GyroGlove Use in Essential Tremor Patients

N/ANot Yet RecruitingNCT05958030

GyroGear Ltd30 enrolled

Overview

This is a multi-centre, single-blind, placebo-controlled trial with an open label follow up. After the baseline assessment, all participants will receive the GyroGlove for two weeks during the open label follow up part of the trial. All gloves will be retrieved and returned to GyroGear after closure of the study.

All participants will attend 2 in-clinic assessment sessions (Baseline (day 0), Follow-up (day 14)) after screening visit. The baseline session will last approximately 120 minutes whilst the 2-week assessment will last approximately 60-80 minutes. At baseline assessment, participants will perform protocol-specific activities with both investigational devices (i.e. GyroGlove and Placebo). In addition to in-clinic assessments, participants will complete self-assessments at Day -3 prior baseline visit (i.e. Day 0,) and at Day 5 and 10 from baseline (i.e. Day 0), when they started using GyroGlove at home. All participants will be blinded at the baseline (Day 0), as assessments will be performed with GyroGlove and a placebo device in a pre-defined sequence. Each participant will act as the control for him/herself and will be blinded to the interventions order. The sequence of interventions in the study has been pre-defined, owing to the potential for longitudinal effects of wearing the device interfering with the accurate study outcome measurement.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

SUPPORTIVE_CARE

Masking

DOUBLE

Enrollment

Conditions

Essential Tremor

Interventions

PlaceboDEVICE

The placebo device consists of the same hardware as GyroGlove: aesthetically it looks the same, weight same and produces the same noise as GyroGlove. Participants will interact with Placebo on the day of baseline visit (i.e. Day 0).

GyroGloveDEVICE

GyroGlove is a patented wearable device containing high-performance, miniaturised, gyroscopes designed for individuals diagnosed with essential tremor. Participants will interact with GyroGlove on the day of baseline visit (i.e. Day 0), 2-week Home use and on the day of follow-up visit (i.e Day 14).

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 18 years of age or older * Subject has been clinically diagnosed with ET * Has either unilateral or bilateral tremor of the hand or predominantly hand as well as forearm * Has a score of ≥ 2 in ADL activities 2, 3, 6 \& 8 of the TETRAS ADL subscale (TRG, Sep 2021) * Tremor in at least one hand causing water spillage during drinking And * Stable dosage of medications throughout the duration of the study, if applicable * Ability to speak and read in the language that the trial documentation has been translated to. * Ability to understand verbal instructions in the language that the trial documentation has been translated to. * Ability to provide written informed consent to participate in the study * Capacity to complete self-report outcome measures in the language that the trial documentation has been translated to Exclusion Criteria: * Other possible causes of tremor, including Parkinson's disease, drug-induced, enhanced physiological tremor * Presence of tremor around the elbow and shoulder limiting participants to perform required test/procedure in the study * Has implanted electrical medical device, e.g., pacemaker, defibrillator, or deep brain stimulator * Clinically diagnosed alcohol use disorder or illicit substance use (exception medical cannabis) * Change in medication for tremor within 1 month prior to study enrolment * Change in antidepressant medication within 3 months prior to study enrolment * Has received botulinum toxin injection for hand tremor within 4 months prior to study enrolment * Has been diagnosed with any of the following conditions affecting the hand and/or arm: * Fingers/Wrist joint defects or deformities or current skeletal injuries that prevent them from wearing the glove * Hand muscular deformities or weakness, e.g.: Myotonic Dystrophy, Autosomal Recessive Muscular Dystrophy limiting participant to perform required test/procedure in the study * Skin Conditions of the hand and forearm, e.g.: Eczema, Psoriasis, Extreme Skin Sensitivity * Growth or Development Defects of the hand, including but not limited to, Brittle Bone Disease, Triphalangeal Thumb. * Previous thalamotomy procedure, including stereotactic thalamotomy, gamma knife radio surgical thalamotomy, and focused ultrasound for the treatment of tremor. * Neurological conditions aside from essential tremor that may affect the conduct of the study * Peripheral neuropathy affecting the upper extremity * Are participating or have participated in any interventional clinical trial or study in the last 30 days which may confound the results of this study, unless approved by the Sponsor * Inability to follow simple instructions * Pregnancy

Locations (7)

Quest Research Institute

Farmington Hills, Michigan, United States

Houston Methodist Stanley H. Appel Department of Neurology

Houston, Texas, United States

University of Vermont Medical Centre

Burlington, Vermont, United States

Addenbrooke Hospital, Cambridge University Hospital NHS Trust

Outcomes

Primary Outcomes

Change from Baseline to Week- 2 (follow-up assessment) on The Essential Tremor Rating Assessment Scale (TETRAS) composite outcome score performance in ET participants

The Essential Tremor Rating Assessment Scale (TETRAS) composite outcome score is the sum of modified items 2, 3, 6 \& 8 of the TETRAS-ADL (Activities of Daily Living) subscale and modified items 6 - 7 of the TETRAS-PS (performance subscale). The TETRAS-ADL subscale is a patient-rated scale administered by a trained interviewer that assesses the impact of tremor on day-to-day functioning, such as feeding with a spoon, drinking from a glass, pouring, using keys etc. The TETARS-PS is a clinical rating scale that quantifies tremor in the head, face, voice, limbs and trunk. Items 6 (drawing an Archimedes spiral) and 7 (handwriting) of the TETRAS-PS evaluate the impact of upper limb tremor on performance. Each item from the modified subscales ranges from 0 - 4, with 0 representing normal and 4 representing severely abnormal. The sum of the 6 items provides the TETRAS composite outcome score, which ranges from 0 - 24, with higher scores representing more severe ET.

Time frame: Day-0 (Baseline) and Day-14 (follow-up)

Secondary Outcomes

Change in performance in a subset of The Essential Tremor Rating Assessment Scale- performance subscales (TETRAS-PS) between GyroGlove and placebo device at baseline in ET participants

TETARS-PS is a clinical rating scale that quantifies tremor in the head, face, voice, limbs and trunk. Items 6 (drawing an Archimedes spiral) and 7 (handwriting) of the TETRAS-PS evaluate the impact of upper limb tremor on performance. Each item from the modified subscales ranges from 0 - 4, with 0 representing normal and 4 representing severely abnormal. The sum of the TETRAS-PS items, which ranges from 0 - 8, with higher scores representing more severe ET.

Time frame: Day-0 (Baseline)

Change in Clinical Global Impression- Improvement scale (CGI-I) score between placebo and GyroGlove

The CGI-I is a 7-point Likert-type rating scale that a qualified medical personnel (ie, a clinician)will use to rate the severity of the participants' ability to function due to their ET. The responses to this scale range from 1 (Very much improved) to 7 (Very much worse).

Central Contacts

Faii Ong

CONTACT

+44 2045773038 clinical@gyrogear.co

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.